Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Trevi Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PROFESSOR PHILIP MOLYNEAUX WILL GIVE AN ORAL PRESENTATION ON THE KEY EFFICACY AND SAFETY RESULTS FROM THE PHASE 2B CORAL TRIAL OF NALBUPHINE ER FOR THE TREATMENT OF CHRONIC COUGH IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) ASSOCIATE PROFESSOR IMRAN SATIA WILL GIVE A POSTER PRESENTATION ON THE PATIENT-REPORTED OUTCOMES FROM THE PHASE 2A RIVER TRIAL OF NALBUPHINE ER FOR THE TREATMENT OF PATIENTS WITH REFRACTORY CHRONIC COUGH (RCC) NEW HAVEN, CONN. , OCT. 8, 2025 /PRNEWSWIRE/ -- TREVI THERAPEUTICS, INC.(NASDAQ: TRVI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING THE INVESTIGATIONAL THERAPY ORAL NALBUPHINE ER FOR THE TREATMENT OF CHRONIC COUGH IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF), NON-IPF INTERSTITIAL LUNG DISEASE (NON-IPF ILD), AND REFRACTORY CHRONIC COUGH (RCC), TODAY ANNOUNCED THE ACCEPTANCE OF TWO ABSTRACTS FOR PRESENTATION AT THE CHEST 2025 ANNUAL MEETING, TO BE HELD FROM OCTOBER 19 TO 22 IN CHICAGO, ILLINOIS.

TREVI THERAPEUTICS ANNOUNCES ORAL PRESENTATION AND ABSTRACTS AT CHEST 2025 ANNUAL MEETING

NEW HAVEN, CONN. , SEPT. 18, 2025 /PRNEWSWIRE/ --TREVI THERAPEUTICS, INC.(NASDAQ: TRVI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING THE INVESTIGATIONAL THERAPY HADUVIO (ORAL NALBUPHINE ER) FOR THE TREATMENT OF CHRONIC COUGH IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF), NON-IPF INTERSTITIAL LUNG DISEASE (NON-IPF ILD), AND REFRACTORY CHRONIC COUGH (RCC), TODAY ANNOUNCED THAT DATA FROM THE PHASE 2A RIVER TRIAL OF NALBUPHINE ERFOR THE TREATMENT OF PATIENTS WITHRCC, WILL BE HIGHLIGHTED IN TWO POSTER PRESENTATIONS AT THE EUROPEAN RESPIRATORY SOCIETY (ERS) CONGRESS 2025.

TREVI THERAPEUTICS ANNOUNCES TWO POSTERS FROM THE PHASE 2A RIVER TRIAL DATA WILL BE FEATURED AT THE EUROPEAN RESPIRATORY SOCIETY (ERS) CONGRESS 2025

NEW HAVEN, CONN. , AUG. 28, 2025 /PRNEWSWIRE/ -- TREVI THERAPEUTICS, INC.(NASDAQ: TRVI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING THE INVESTIGATIONAL THERAPY HADUVIO (ORAL NALBUPHINE ER) FOR THE TREATMENT OF CHRONIC COUGH IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF), NON-IPF INTERSTITIAL LUNG DISEASE (NON-IPF ILD), AND REFRACTORY CHRONIC COUGH (RCC), TODAY ANNOUNCED THAT SENIOR MANAGEMENT WILL BE PARTICIPATING IN THE FOLLOWING CONFERENCES IN SEPTEMBER.

TREVI THERAPEUTICS TO PARTICIPATE IN UPCOMING SEPTEMBER CONFERENCES

ANNOUNCED POSITIVE TOPLINE RESULTS FROM ITS PHASE 2B CORAL TRIAL OF HADUVIO FOR THE TREATMENT OF CHRONIC COUGH IN PATIENTS WITH IPF CLOSED $115 MILLION UNDERWRITTEN OFFERING WITH EXPECTED CASH RUNWAY INTO 2029 MANAGEMENT TO HOST A CONFERENCE CALL AND WEBCAST TODAY AT 4:30 P.M. ET NEW HAVEN, CONN.

TREVI THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

CONFERENCE CALL AND WEBCAST TO BE HELD AT 4:30 P.M. ET  NEW HAVEN, CONN.

TREVI THERAPEUTICS TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON AUGUST 7, 2025

NEW HAVEN, CONN. , JULY 29, 2025 /PRNEWSWIRE/ --TREVI THERAPEUTICS, INC.(NASDAQ: TRVI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING THE INVESTIGATIONAL THERAPY HADUVIO (ORAL NALBUPHINE ER) FOR THE TREATMENT OF CHRONIC COUGH IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF), NON-IPF INTERSTITIAL LUNG DISEASE (NON-IPF ILD), AND REFRACTORY CHRONIC COUGH (RCC), TODAY ANNOUNCED THAT SENIOR MANAGEMENT WILL BE PARTICIPATING IN THE FOLLOWING CONFERENCES IN AUGUST.

TREVI THERAPEUTICS TO PARTICIPATE IN UPCOMING AUGUST CONFERENCES

NEW HAVEN, CONN. , JULY 1, 2025 /PRNEWSWIRE/ -- TREVI THERAPEUTICS, INC.(NASDAQ: TRVI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING THE INVESTIGATIONAL THERAPY HADUVIO (ORAL NALBUPHINE ER) FOR THE TREATMENT OF CHRONIC COUGH IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) AND IN PATIENTS WITH REFRACTORY CHRONIC COUGH (RCC), TODAY ANNOUNCED THAT JENNIFER GOOD, PRESIDENT AND CHIEF EXECUTIVE OFFICER, AND LISA DELFINI, CHIEF FINANCIAL OFFICER, WILL BE ATTENDING LEERINK PARTNERS THERAPEUTICS FORUM: I&I AND METABOLISM, HELD FROM JULY 8-9 IN BOSTON, MASSACHUSETTS.

TREVI THERAPEUTICS TO ATTEND LEERINK PARTNERS THERAPEUTICS FORUM: I&I AND METABOLISM

NEW HAVEN, CONN. , JUNE 5, 2025 /PRNEWSWIRE/ -- TREVI THERAPEUTICS, INC.(NASDAQ: TRVI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING THE INVESTIGATIONAL THERAPY HADUVIO(ORAL NALBUPHINE ER) FOR THE TREATMENT OF CHRONIC COUGH IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) AND IN PATIENTS WITH REFRACTORY CHRONIC COUGH (RCC), TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 20,010,000 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $5.75 PER SHARE, WHICH INCLUDES 2,610,000 ADDITIONAL SHARES ISSUED UPON THE EXERCISE IN FULL BY THE UNDERWRITERS OF THEIR OPTION TO PURCHASE ADDITIONAL SHARES OF COMMON STOCK IN THE PUBLIC OFFERING AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS.

TREVI THERAPEUTICS ANNOUNCES CLOSING OF $115 MILLION UNDERWRITTEN OFFERING AND FULL EXERCISE BY UNDERWRITERS OF OPTION TO PURCHASE ADDITIONAL SHARES

NEW HAVEN, CONN. , JUNE 3, 2025 /PRNEWSWIRE/ --TREVI THERAPEUTICS, INC.(NASDAQ: TRVI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING THE INVESTIGATIONAL THERAPY HADUVIO(ORAL NALBUPHINE ER) FOR THE TREATMENT OF CHRONIC COUGH IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) AND IN PATIENTS WITH REFRACTORY CHRONIC COUGH (RCC), TODAY ANNOUNCED THE PRICING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 17,400,000 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $5.75 PER SHARE, FOR TOTAL PROCEEDS OF $100 MILLION, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND EXPENSES PAYABLE BY TREVI.

TREVI THERAPEUTICS ANNOUNCES PRICING OF $100 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK

NEW HAVEN, CONN. , JUNE 2, 2025 /PRNEWSWIRE/ -- TREVI THERAPEUTICS, INC. (NASDAQ: TRVI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING THE INVESTIGATIONAL THERAPY HADUVIO (ORAL NALBUPHINE ER) FOR THE TREATMENT OF CHRONIC COUGH IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) AND IN PATIENTS WITH REFRACTORY CHRONIC COUGH (RCC), TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $100,000,000 OF SHARES OF ITS COMMON STOCK.

Trevi Therapeutics, Inc.

TRVI

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Trevi Therapeutics, Inc.

TRVI.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

TRVI